Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Century Therapeutics ( (IPSC) ) is now available.
On December 18, 2025, Century Therapeutics, Inc. announced that board member Carlo Rizzuto, Ph.D., resigned from its board of directors, effective the same day. The company emphasized that Rizzuto’s departure did not arise from any disagreement over its operations, policies, or practices, and publicly expressed appreciation for his distinguished service and lasting contributions to the organization.
The most recent analyst rating on (IPSC) stock is a Hold with a $0.90 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.
Spark’s Take on IPSC Stock
According to Spark, TipRanks’ AI Analyst, IPSC is a Neutral.
Century Therapeutics’ stock score is driven by strong technical momentum and positive corporate developments. However, financial performance and valuation remain weak due to ongoing losses and negative cash flow.
To see Spark’s full report on IPSC stock, click here.
More about Century Therapeutics
Average Trading Volume: 1,277,926
Technical Sentiment Signal: Sell
Current Market Cap: $94.83M
For an in-depth examination of IPSC stock, go to TipRanks’ Overview page.